Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Stock Short Interest Report for September

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) saw a significant decline in short interest in September. As of September 30th, there was short interest totaling 10,544 shares, a decline of 87.1% from the September 15th total of 81,947 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 215,472 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Weiss Ratings upgraded Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. Wall Street Zen upgraded Chemomab Therapeutics to a “hold” rating in a report on Saturday, October 3rd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Reduce”.

Institutional Trading of Chemomab Therapeutics

A hedge fund recently raised its position in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC lifted its holdings in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 19.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 61,710 shares of the company’s stock after acquiring an additional 10,000 shares during the quarter. Kestra Private Wealth Services LLC owned 0.86% of Chemomab Therapeutics worth $97,000 as of its most recent filing with the SEC. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Stock Performance

Shares of CMMB stock traded down $0.01 on Friday, hitting $1.38. The stock had a trading volume of 12,203 shares, compared to its average volume of 150,403. The firm has a market capitalization of $10.01 million, a price-to-earnings ratio of -0.65 and a beta of 0.74. The stock’s 50 day moving average is $2.13 and its 200-day moving average is $1.84. Chemomab Therapeutics has a 52-week low of $1.05 and a 52-week high of $3.50.

Chemomab Therapeutics (NASDAQ:CMMB) last released its quarterly earnings results on Thursday, August 20th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.12).

About Chemomab Therapeutics

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory and fibrotic diseases. The company’s research is centered on CCL24, a chemokine believed to contribute to inflammation, fibrosis and tissue damage across several disease areas.

Chemomab’s lead product candidate is CM-101, a proprietary monoclonal antibody designed to block CCL24 activity. The therapy has been evaluated in clinical studies for conditions including primary sclerosing cholangitis, a progressive liver disease, and systemic sclerosis, an autoimmune disorder that can cause widespread fibrosis.